Anti-GD2 Strategy in the Treatment of Neuroblastoma

Overview

Journal Drugs Future

Publisher Thomson Reuters

Specialty Pharmacology

Date 2010 Nov 2

PMID 21037966

Citations 39

Authors

Richard K Yang

Paul M Sondel

Affiliations

Soon will be listed here.

Abstract

The prognosis for advanced neuroblastoma remains poor with high risk of recurrence after consolidation. Therapies based on monoclonal antibodies that specifically target disialoganglioside GD2 on tumor cells are improving treatment results for high-risk neuroblastoma. This article reviews the use of anti-GD2 antibodies either as monotherapy or as part of a larger and more complex treatment approach for advanced neuroblastoma. We review how anti-GD2 antibodies can be combined with other treatments or strategies to enhance their clinical effects. Tumor resistance and other problems that decrease the efficacy of anti-GD2 antibodies are discussed. Future developments in the area of anti-GD2 immunotherapies for neuroblastoma are also addressed.

Citing Articles

The Glycocalyx: The Importance of Sugar Coating the Blood-Brain Barrier.

Dancy C, Heintzelman K, Katt M Int J Mol Sci. 2024; 25(15).

PMID: 39125975 PMC: 11312458. DOI: 10.3390/ijms25158404.

Adoptive Cellular Therapy for Pediatric Solid Tumors: Beyond Chimeric Antigen Receptor-T Cell Therapy.

Hensel J, Metts J, Gupta A, Ladle B, Pilon-Thomas S, Mullinax J Cancer J. 2022; 28(4):322-327.

PMID: 35880942 PMC: 9847472. DOI: 10.1097/PPO.0000000000000603.

Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.

Mora J, Chan G, Morgenstern D, Nysom K, Bear M, Tornoe K Cancer Rep (Hoboken). 2022; 6(1):e1627.

PMID: 35579862 PMC: 9875606. DOI: 10.1002/cnr2.1627.

The Thermal Dose of Photothermal Therapy Generates Differential Immunogenicity in Human Neuroblastoma Cells.

Sekhri P, Ledezma D, Shukla A, Sweeney E, Fernandes R Cancers (Basel). 2022; 14(6).

PMID: 35326601 PMC: 8945975. DOI: 10.3390/cancers14061447.

Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.

Wu D, Berg J, Arlt B, Rohrs V, Al-Zeer M, Deubzer H Int J Mol Sci. 2022; 23(1).

PMID: 35008547 PMC: 8745467. DOI: 10.3390/ijms23010122.

References

Wang X, Luo W, Foon K, Ferrone S . Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. Cancer Chemother Biol Response Modif. 2001; 19:309-26. View

Cheung I, Lo Piccolo M, Kushner B, Cheung N . Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol. 2003; 21(20):3853-8. DOI: 10.1200/JCO.2003.11.077. View

Cheung N, Saarinen U, Neely J, Landmeier B, Donovan D, Coccia P . Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985; 45(6):2642-9. View

Modak S, Cheung N . Antibody-based targeted radiation to pediatric tumors. J Nucl Med. 2005; 46 Suppl 1:157S-63S. View

Gillies S, Young D, Lo K, Roberts S . Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem. 1993; 4(3):230-5. DOI: 10.1021/bc00021a008. View

Cheung N . Monoclonal antibody-based therapy for neuroblastoma. Curr Oncol Rep. 2000; 2(6):547-53. DOI: 10.1007/s11912-000-0109-6. View

Chatterjee M, Mrozek E, Vaickus L, Oseroff A, Stoll H, Russell D . Antiidiotype (Ab2) vaccine therapy for cutaneous T-cell lymphoma. Ann N Y Acad Sci. 1993; 690:376-7. DOI: 10.1111/j.1749-6632.1993.tb44036.x. View

Kushner B, LaQuaglia M, Bonilla M, Lindsley K, Rosenfield N, Yeh S . Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994; 12(12):2607-13. DOI: 10.1200/JCO.1994.12.12.2607. View

Brodeur G . Significance of intratumoral genetic heterogeneity in neuroblastomas. Med Pediatr Oncol. 2002; 38(2):112-3. DOI: 10.1002/mpo.1282. View

10.

Yeh S, Larson S, Burch L, Kushner B, LaQuaglia M, Finn R . Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med. 1991; 32(5):769-76. View

11.

Cheung N, Modak S . Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002; 8(5):1217-23. View

12.

Cheung N, Walter E, Ratnoff W, Tykocinski M, Medof M . Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988; 81(4):1122-8. PMC: 329640. DOI: 10.1172/JCI113426. View

13.

Cheung N, Kushner B, Kramer K . Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am. 2002; 15(5):853-66. DOI: 10.1016/s0889-8588(05)70255-0. View

14.

Gillies S, REILLY E, Lo K, Reisfeld R . Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A. 1992; 89(4):1428-32. PMC: 48464. DOI: 10.1073/pnas.89.4.1428. View

15.

Luo W, Ko E, Hsu J, Wang X, Ferrone S . Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol. 2006; 176(10):6046-54. DOI: 10.4049/jimmunol.176.10.6046. View

16.

Fisch P, Prieve A, Sosman J, Hank J, Sondel P . Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res. 1989; 49(13):3680-8. View

17.

Mule J, Yang J, Afreniere R, Shu S, Rosenberg S . Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol. 1987; 139(1):285-94. View

18.

Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J . A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother. 1992; 35(3):199-204. PMC: 11038881. DOI: 10.1007/BF01756188. View

19.

Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D . Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004; 22(17):3549-57. DOI: 10.1200/JCO.2004.08.143. View

20.

Chatterjee M, Barcos M, Han T, Liu X, Bernstein Z, Foon K . Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma. Blood. 1990; 76(9):1825-9. View